A Phase 4 interventional study of Dexycu in Inflammation and Cataract, sponsored by Ocumension Therapeutics (Shanghai) Co., Ltd. Completed at 2 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.
Among the 34 studies testing dexamethasone in Cataract, this one is the 6th largest by enrollment, is one of 7 that started in 2021, is one of 18 in phase 4, and was the 31st registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V. · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 10 · Phase 4 18
First in 2004; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 50 across the 34 interventional studies. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 34 have an industry lead sponsor. The 10 most frequent:
Ocumension Therapeutics (Shanghai) Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.
Ocumension Therapeutics (Shanghai) Co., Ltd has 2 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing dexamethasone in Cataract, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.
To evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts in real-world clinical settings, medical history and follow-up data from 113 subjects of Dexycu group and 150 subjects of external control group will be prospectively collected in Hainan, China. Additionally, questionnaires will be collected from surgeons on 30 cases to evaluate the difficulty, duration and safety of the Dexycu injector.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
This study's enrollment of 263 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Browse Cataract studies →Ocumension Therapeutics (Shanghai) Co., Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.
Compared within Cataract, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single injection of DEXYCU in the treatment eye after cataract surgery.
Drug: Dexycu
The clinical routine treatment after cataract surgery was adopted without intervention
single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
Anterior Chamber Cell Clearing Rate
The primary outcome is to compare the ratio of subjects with anterior chamber cell grade 0 at day 8 after cataract surgery of both Dexycu group and external control group. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).
Time frame: DAY 8
113 recruited to the study group treat with DEXYCU postsurgerically. 150 recruited to control group which observation study was conducted.
| Milestone | Control Group | Study Group |
|---|---|---|
| Started | 150 | 113 |
| Completed | 143 | 110 |
| Not completed | 7 | 3 |
The primary outcome is to compare the ratio of subjects with anterior chamber cell grade 0 at day 8 after cataract surgery of both Dexycu group and external control group. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).
| Participants | Control Group | Study Group |
|---|---|---|
| Anterior Chamber Cell Clearing Rate | 119 | 95 |
Collected over Through study completion, an average of 90 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Group | 0/150 (0%) | 5/150 (3.3%) | 14/150 (9.3%) |
| Study Group | 1/113 (0.9%) | 1/113 (0.9%) | 15/113 (13.3%) |
| Event | Control Group | Study Group |
|---|---|---|
| Macular OedemaEye disorders | 4/150 | 0/113 |
| EndophthalmitisEye disorders | 0/150 | 1/113 |
| DiplopiaEye disorders | 1/150 | 0/113 |
| Event | Control Group | Study Group |
|---|---|---|
| Corneal endothelial cell lossEye disorders | 14/150 | 15/113 |
| Age, Customized(Participants) | Control Group | Study Group | Total |
|---|---|---|---|
| < = 60 years | 15 | 17 | 32 |
| > 60 years | 135 | 96 | 231 |
| Sex: Female, Male(Participants) | Control Group | Study Group | Total |
|---|---|---|---|
| Female | 84 | 55 | 139 |
| Male | 66 | 58 | 124 |
| Race (NIH/OMB)(Participants) | Control Group | Study Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 150 | 113 | 263 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Control Group | Study Group | Total |
|---|---|---|---|
| China | 149 | 113 | 262 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Jul 2023, 20 months.
Results were first posted in Sep 2025, 2 years 1 month after primary completion.
Of 46 phase 4 interventional studies under Cataract, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Ocumension Therapeutics (Shanghai) Co., Ltd